Pamrevlumab is a monoclonal antibody designed to inhibit connective tissue growth factor (CTGF), a protein involved in fibrosis and tumor progression. It has shown therapeutic potential in several clinical conditions characterized by excessive tissue scarring or abnormal cell proliferation.

In idiopathic pulmonary fibrosis (IPF), pamrevlumab helps reduce lung function decline by targeting the fibrotic process, potentially slowing disease progression. It is also being investigated in pancreatic cancer, where it may disrupt the dense fibrotic tumor microenvironment, improving chemotherapy delivery and enhancing treatment efficacy. Clinical trials have explored its use in combination with standard chemotherapies to improve outcomes in locally advanced pancreatic cancer.

Additionally, pamrevlumab is under study for Duchenne muscular dystrophy (DMD), where it aims to reduce muscle fibrosis and preserve muscle function. By blocking CTGF activity, it may help maintain mobility and respiratory function in affected individuals.

Overall, pamrevlumab represents a targeted approach to diseases driven by fibrosis and stromal remodeling, offering a novel mechanism to complement existing therapies.